Health Catalyst (HCAT)
(Delayed Data from NSDQ)
$7.26 USD
+0.32 (4.61%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $7.36 +0.10 (1.38%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HCAT 7.26 +0.32(4.61%)
Will HCAT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HCAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HCAT
Time to Play 5 Top-Ranked Stocks With Rising P/E?
Do Options Traders Know Something About Health Catalyst (HCAT) Stock We Don't?
HCAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
Why Health Catalyst (HCAT) Might be Well Poised for a Surge
Other News for HCAT
Health Catalyst announces new credit facility for up to $225M
Health Catalyst Announces New Credit Facility for up to $225,000,000
Health Catalyst: Stellar Earnings Growth Projected
Analysts Offer Insights on Healthcare Companies: Inari Medical (NARI) and Health Catalyst (HCAT)
Health Catalyst Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)